Leading the Charge

We’ve built a company poised to produce transformative pharmaceutical solutions by bringing together leaders steeped in all the functional areas needed to bring new drugs to life. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we’re acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need.

Meet Our Best & Brightest

Bringing products to market for patients with high unmet medical need. Managing quality and regulatory compliance for a global biotech company. Overseeing clinical development for top-flight pharmaceutical companies. These are the back stories of just some of the bright minds you’ll find in the lab, meeting room and beyond at Dova Pharmaceuticals.


David Zaccardelli, PharmD
President and Chief Executive Officer

Dr. Zaccardelli joined Dova Pharmaceuticals as President and CEO in December 2018. Prior to joining Dova, he served as the Acting Chief Executive Officer of Cempra, Inc. (NASDAQ: CEMP) from December 2016 until the company’s merger with Melinta Therapeutics, Inc (NASDAQ: MLNT) in November 2017. From 2004 until 2016, Dr. Zaccardelli served in several senior management roles at United Therapeutics Corporation (NASDAQ: UTHR), including chief operating officer, chief manufacturing officer and executive vice president, pharmaceutical development and operations. Prior to joining United Therapeutics, Dr. Zaccardelli founded and led a startup company focused on contract pharmaceutical development services, from 1997 through 2003. From 1988 to 1996, Dr. Zaccardelli worked at Burroughs Wellcome & Co. and Glaxo Wellcome, Inc. in a variety of clinical research positions. He also served as director of clinical and scientific affairs for Bausch & Lomb Pharmaceuticals from 1996 to 1997. Dr. Zaccardelli currently serves on the board of directors of Melinta as well as Evecxia, Inc. and CoreRx, Inc., both privately held companies. Dr. Zaccardelli received a Pharm.D. from the University of Michigan and completed a Fellowship in Clinical Research and Drug Development at the University of North Carolina and Burroughs Wellcome Co.